Target Name: REV1
NCBI ID: G51455
Review Report on REV1 Target / Biomarker Content of Review Report on REV1 Target / Biomarker
REV1
Other Name(s): Alpha integrin-binding protein 80 | DNA repair protein REV1 | REV1-like | REV1 DNA directed polymerase | REV1L | REV1- like | REV1 (yeast homolog)- like | MGC26225 | AIBP80 | REV1 variant 1 | REV1 homolog | DNA repair protein REV1 (isoform 1) | FLJ21523 | REV1_HUMAN | alpha integrin-binding protein 80 | rev1-like terminal deoxycytidyl transferase | Rev1-like terminal deoxycytidyl transferase | REV1 DNA directed polymerase, transcript variant 1 | REV1, polymerase (DNA directed) | MGC163283

REV1: A Potential Drug Target and Biomarker for Alpha Integrin-Binding Protein 80

Abstract:

Alpha integrin-binding protein 80 (REV1) is a protein that plays a critical role in cell-cell adhesion, migration, and invasion. It is a transmembrane protein that contains a unique N-terminal domain, a unique C-terminal domain, and a unique N-terminal and C-terminal region. REV1 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

Introduction:

Alpha integrin-binding protein 80 (REV1) is a transmembrane protein that is involved in various cellular processes, including cell-cell adhesion, migration, and invasion. It is a critical protein that helps maintain the integrity of the endothelial barrier, which is responsible for maintaining blood flow and oxygenation. REV1 has also been shown to play a role in the regulation of cell cycle progression and apoptosis.

Despite its importance, REV1 has not yet been fully characterized, and its potential functions and interactions with other proteins are not well understood. However, research has shown that REV1 can be targeted by small molecules, making it a promising target for drug development.

Targeting REV1:

One of the most promising strategies for targeting REV1 is the use of small molecules that can inhibit its activity. Several studies have shown that small molecules such as inhibitors of the RhoA GTPase, which is a key regulator of cell cycle progression, can inhibit REV1's activity.

Another approach to targeting REV1 is the use of antibodies that can specifically recognize and bind to its N-terminus. This approach has been shown to be effective in several models of cancer, including breast cancer and ovarian cancer.

Biomarker identification:

REV1 has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Several studies have shown that levels of REV1 are altered in these diseases, and that inhibiting its activity may be a promising strategy for the development of new treatments.

For example, several studies have shown that REV1 is overexpressed in breast cancer, and that inhibiting its activity may be a promising strategy for the development of new treatments. Similarly, several studies have shown that REV1 is overexpressed in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, and that inhibiting its activity may be a promising strategy for the development of new treatments.

Conclusion:

In conclusion, REV1 is a protein that plays a critical role in cell-cell adhesion, migration, and invasion. Its unique N-terminal domain, C-terminal domain, and N-terminal and C-terminal regions make it a unique protein that has not yet been fully characterized. However, research has shown that REV1 can be targeted by small molecules, and that it can be used as a potential drug target and biomarker for various diseases. Further research is needed to fully understand its functions and interactions with other proteins.

Protein Name: REV1 DNA Directed Polymerase

Functions: Deoxycytidyl transferase involved in DNA repair. Transfers a dCMP residue from dCTP to the 3'-end of a DNA primer in a template-dependent reaction. May assist in the first step in the bypass of abasic lesions by the insertion of a nucleotide opposite the lesion. Required for normal induction of mutations by physical and chemical agents

The "REV1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about REV1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

REV3L | Reverse transcriptase (Telomerase) | REX1BD | REXO1 | REXO1L1P | REXO1L2P | REXO1L6P | REXO1L8P | REXO2 | REXO4 | REXO5 | RFC1 | RFC2 | RFC3 | RFC4 | RFC5 | RFESD | RFESDP1 | RFFL | RFK | RFLNA | RFLNB | RFNG | RFPL1 | RFPL1S | RFPL2 | RFPL3 | RFPL3S | RFPL4A | RFPL4AL1 | RFPL4B | RFT1 | RFTN1 | RFTN2 | RFWD3 | RFX complex | RFX1 | RFX2 | RFX3 | RFX3-DT | RFX4 | RFX5 | RFX5-AS1 | RFX6 | RFX7 | RFX8 | RFXANK | RFXAP | RGCC | RGL1 | RGL2 | RGL3 | RGL4 | RGMA | RGMB | RGMB-AS1 | RGN | RGP1 | RGPD1 | RGPD2 | RGPD3 | RGPD4 | RGPD4-AS1 | RGPD5 | RGPD6 | RGPD8 | RGR | RGS1 | RGS10 | RGS11 | RGS12 | RGS13 | RGS14 | RGS16 | RGS17 | RGS18 | RGS19 | RGS2 | RGS20 | RGS21 | RGS22 | RGS3 | RGS4 | RGS5 | RGS6 | RGS7 | RGS7BP | RGS8 | RGS9 | RGS9BP | RGSL1 | RHAG | RHBDD1 | RHBDD2 | RHBDD3 | RHBDF1 | RHBDF2 | RHBDL1 | RHBDL2 | RHBDL3